Article
Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.
Hepatology (Baltimore, Md.) - 1 Apr 2006
Liu Chun-Jen, Lai Ming-Yang, Chao You-Chen, Liao Li-Ying, Yang Sien-Sing, Hsiao Tun-Jen, Hsieh Tsai-Yuan, Lin Chih-Lin, Hu Jui-Ting, Chen Chi-Ling, Chen Per-Jer, Kao Jia-Horng, Chen Ding-Shinn
Abstract excerpt
To study whether interferon (IFN) alpha and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-alpha2b daily for 4 weeks followed by 5 million units three times a week for 28 weeks, plus 1,200 mg ribavirin daily. Sixty patients received the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.